GlassScriptPhysician profile
Ailia Rizvi
NPI 1093050072
$2,839.11
in general payments reported to CMS, 2019-2025
14 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.35 · 2022: $1,127 · 2023: $700 · 2024: $754 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.64 |
| Education | $257.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,624.94 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Heartmate Touch |
| Actelion Pharmaceuticals US, INC. | $330.83 | 2023-2025 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.07 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $147.91 | 2022-2024 | Verquvo |
| Kestra Medical Technology Services, INC. | $117.59 | 2023-2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $87.26 | 2023-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.12 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $57.09 | 2023-2025 | Farxiga |
| Pfizer INC. | $36.22 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $29.29 | 2022-2025 | Camzyos |
| Scpharmaceuticals INC. | $27.05 | 2023 | |
| Daxor Corporation | $25.27 | 2023 | Bva-100 |
| Novo Nordisk INC | $23.08 | 2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ailia Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.